Quiet Therapeutics
Anticancer Therapeutics Using Nanoparticles and Biomarkers
Company Overview
Snapshot
Founded in January 2010, Quiet Therapeutics operates with 1–10 employees. The company has raised $18.5M across three funding rounds from four investors.
Business overview
Quiet Therapeutics is a cancer drug discovery and development company focused on creating a new generation of cancer therapeutics. The company utilizes its proprietary GAGomer technology to specifically target tumor cells, delivering a therapeutic payload that leads to cancer cell death. This technology allows for flexibility in treatment, enabling the delivery of medicines that can kill cancer cells, block protein production that promotes cancer, or use cancer cells' own machinery to produce therapeutic proteins. Quiet Therapeutics develops a diverse set of DNA, RNA, and small molecule anticancer therapeutics, operating within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals.
Strategic signal
In January 2015, Quiet Therapeutics was highlighted for its innovative approach to cancer treatment, specifically its use of nanoparticles to attack cancer cells. This recognition underscores the potential of its GAGomer technology to revolutionize targeted therapy in oncology, signaling to investors a strong validation of its scientific foundation and future market relevance in the biotechnology and pharmaceutical industries.
Company Intelligence Q&A
- What is Quiet Therapeutics' primary focus?
- Quiet Therapeutics is focused on developing anticancer therapeutics using nanoparticles and biomarkers, aiming to create a new generation of cancer treatments.
- When was Quiet Therapeutics founded?
- Quiet Therapeutics was founded in January 2010.